Related Experiment Video
Updated: Jul 30, 2026
09:33
Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
[Alzheimer disease: cellular and molecular aspects]
Bulletin Et Memoires De L'Academie Royale De Medecine De Belgique
|June 14, 2006
Summary
Alzheimer's disease diagnosis relies on neurofibrillary tangles (NFTs) and amyloid plaques. Inhibiting amyloid-beta (Abeta) production or aggregation shows promise in slowing cognitive decline and reducing plaques.
Area of Science:
- Neuropathology
- Neuroscience
- Molecular Biology
Background:
- Alzheimer's disease (AD) diagnosis correlates clinical findings with post-mortem neuropathology.
- Key neuropathological hallmarks include neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau protein and extracellular amyloid plaques containing amyloid-beta (Abeta) peptides.
- NFTs are linked to microtubule collapse, impaired axonal transport, and neuronal death, while Abeta deposits form senile plaques.
Discussion:
- Amyloid precursor protein (APP) catabolism involves non-amyloidogenic and amyloidogenic pathways.
- The amyloidogenic pathway, involving beta- and gamma-secretase cleavage, produces Abeta peptides, with intraneuronal Abeta aggregation inducing neuronal apoptosis.
- Inhibition of secretase activity or Abeta aggregation is a therapeutic strategy to reduce Abeta production and toxicity.
Key Insights:
- Hyperphosphorylated tau forms NFTs, disrupting neuronal function and transport.
- Amyloid plaques are formed by aggregated Abeta peptides, derived from APP processing.
- Intraneuronal Abeta accumulation is toxic to neurons, potentially driving AD pathogenesis.
Outlook:
- Therapeutic strategies focus on inhibiting secretase enzymes to reduce Abeta production.
- Developing molecules to inhibit Abeta aggregation and exploring Abeta-targeted immunization are ongoing research areas.
- While early Abeta immunization trials faced challenges, preliminary data suggest potential benefits in slowing cognitive decline and clearing plaques.
Related Concept Videos
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...